Be a Part of the Fight to End Alzheimer's
Be a Part of the Fight to End Alzheimer's
The millions of people impacted by Alzheimer's disease need your help. Your generosity can help us provide care and support to those facing the challenges of Alzheimer's and advance global research. Please make a gift today.
Donate NowAlzheimer's Association Part the Cloud Grants $11 Million to Develop Innovative Treatments
Catalyzing the expansion of the clinical trials pipeline for Alzheimer's treatments has never been more essential. For more than a decade, Part the Cloud has led the vanguard of investments in new treatment approaches and accelerating the pace of the clinical trials pipeline..
In 2012, Part the Cloud was started by philanthropist Michaela “Mikey” Hoag, whose visionary leadership provided urgently needed funding to fill gaps in support for early to mid-phase clinical trials. Part the Cloud’s funding model emphasizes groundbreaking high-risk, high-reward projects.
There is no other funding mechanism with the scope and breadth of Part the Cloud. Its proven success is demonstrated by the more than $1.6 billion in follow-on funding from the federal government, venture capital firms and other sources. Part the Cloud is specifically designed to speed up translation of experimental treatments from the laboratory into high-quality studies in people.
“Today we are in an era of unprecedented promise in the race to end Alzheimer's and other diseases that cause dementia,” said Hoag. “I am proud to champion Part the Cloud and its investment into these trailblazing projects as they push to speed up breakthroughs and transform care.”
“Because of Part the Cloud, we are generating real international scientific progress in new potential treatments,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead. “Now more than ever, it is crucial to support forward-looking projects that can generate hope for the future. This round of Part the Cloud awards catalyzes dynamic projects across three focus areas: early phase clinical trials evaluating novel or repurposed medications or combinations; early phase trials targeting the genetics of Alzheimer's; and the funding essential to advance the preclinical work to first-in-human clinical trials."
Each of the 11 grants is for approximately $1 million. The new Part the Cloud grant awardees are:
Translational Research Grant Program
- Glenn Larsen, Ph.D., Aquinnah Pharmaceuticals, Inc. Tauopathy Therapeutic AQV-8741: A Phase I Study.
- Terry Goldberg, Ph.D., Research Foundation for Mental Hygiene, Inc. at New York State Psychiatric Institute. Vortioxetine to improve synaptic connectivity.
- Luis Oskar Soto-Rojas, Ph.D., National Autonomous University of Mexico. Creatine-Augmented Exercise for Neuroprotection in Early AD patients.
- Timothy Siegert, Ph.D., Allyx Therapeutics, Inc. A Phase 2A Trial of ALX-001 (BMS-984923).
- Alireza Faridar, M.D., The Methodist Hospital Research Institute. IL-2 plus GLP-1 RA Combination Therapy to Target Inflammation in AD.
- Rita Balice-Gordon, Ph.D., Muna Therapeutics. Small Molecule TREM2 Agonism: Phase 1 and Observational Studies in Early AD.
- Evan Lebois, Ph.D., Violet Therapeutics, Inc. Novel small molecule EPHB3 inhibitors to prevent AD synapse loss.
- Anindya Bhattacharya, Ph.D., Switch Therapeutics, Inc. Targeting MAPT knockdown by a unique siRNA platform to treat Alzheimer's.
- Can Zhang, M.D., Ph.D., and Changning Wang, Ph.D., Massachusetts General Hospital. Discovery of novel epigenetic inhibitors for Alzheimer’s disease.
- Mark Heiman, Ph.D., and Adrian Noriega, M.D., Ph.D., Pramana Pharmaceuticals Inc. IND readiness for PRM914 a Novel Oral Gut-Brain treatment for Alzheimer's.
- Judith Kelleher-Andersson, Ph.D., Neuronascent, Inc. Aged CCD Field Trial for Go-no-go Decision of NNI-362 Ph2 POC Trial.
To learn more about Part the Cloud, including current and future funding opportunities, visit alz.org/partthecloud.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.